In 2016, two major trials provided conflicting evidence regarding the role of 1 year of adjuvant therapy with sunitinib for patients with high-risk renal-cell carcinoma. In the second-line metastatic setting, updated data from key trials showed that cabozantinib improved overall survival over everolimus, and nivolumab was associated with a better quality of life compared with everolimus. Finally, a phase II study in previously untreated patients showed cabozantinib to be superior to sunitinib.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma
World Journal of Surgical Oncology Open Access 14 April 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814–1823 (2015).
Motzer, R. J. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 16, 1473–1782 (2015).
Haas, N. B. et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008–2016 (2016).
Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).
Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 917–927 (2016).
Cella, D. et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 17, 994–1003 (2016).
Choueiri, T. K. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.70.7398 (2016).
Armstrong, A. J. et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 17, 378–388 (2016).
Tannir, N. M. et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur. Urol. 69, 866–874 (2015).
Motzer, R. J. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 2765–2772 (2014).
Bex, A. et al. Updated european association of urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.11.034 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.A. declares that she is a consultant for and has an advisory role with Amgen, Bayer, Bristol-Myers Squibb, Cerulean, Novartis, Pfizer, and Sanofi, and receives research funding from Novartis and Pfizer. T.K.C. declares he is a consultant for and has an advisory role to Bayer, Bristol-Myers Squibb, Exelixis, GSK, Merck, Novartis, and Pfizer. He also receives research funding from AstraZeneca, Bristol-Myers Squibb, Exelixis, GSK, Merck, Novartis, Peloton, Pfizer, Roche, and Tracon.
Rights and permissions
About this article
Cite this article
Albiges, L., Choueiri, T. Advances in treatment — jostling for pole position. Nat Rev Clin Oncol 14, 82–84 (2017). https://doi.org/10.1038/nrclinonc.2016.224
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.224
This article is cited by
-
Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma
World Journal of Surgical Oncology (2022)